A Phase I Dose-Escalation Study of the Selective PKC- Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of MS-553 in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Sponsor: MindSight Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR9532
U.S. Govt. ID: NCT03492125
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: MS-553 is being tested for its potential to block a specific enzyme (Protein Kinase C) that is known to play a role in the growth and survival of cancer cells in different types of leukemia. The purpose of this study is to determine the safety, recommended dose and preliminary activity of MS-553 in treating CLL/SLL.
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have CLL or SLL? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE